MetrioPharm AG Investor Relations News
-
Investor Relations News QIII 2022
MetrioPharm at BioPharm America in Boston, USA, Company Calendar in QIV 2022, MetrioPharm blog, MetrioPharm at Linkedin
-
Investor Relations News QII 2022
16th Annual General Meeting of MetrioPharm AG, Bio-Europe Spring in Basel, BIO International Convention in San Diego, Company Calendar, London-Paris in 24 hours, MetrioPharm AG informs
-
Investor Relations News QI 2022
Outlook by the Chairman of the Board Rudolf Stäger
-
Investor Relations News QIV 2021
Greetings from CEO Thomas Christély
-
Investor Relations News QIII 2021
Topics: Greetings from CEO Thomas Christély, MetrioPharm in the Media
-
Investor Relations News QII 2021
Topics: 15th Annual General Meeting of MetrioPharm AG, MetrioPharm in the Media
-
Investor Relations News QI 2021
Holiday Greetings from CEO Dr. Wolfgang Brysch
-
Investor Relations News Update
MetrioPharm in the media (ARD, RBB): "The necessity of therapeutics in the fight against the corona pandemic", "Possible use of MP1032 in acute illness of patients with Covid-19"
-
MetrioPharm Investor Relations News QIV 2020
Greetings by CEO Dr. Wolfgang Brysch: "Our lead compound MP1032 is a highly promising candidate for the treatment of Covid-19.", MetrioPharm in the Media
-
Investor Relations News Update
MetrioPharm announced that it is preparing a Phase II clinical trial for its lead compound MP1032 in the fight against COVID-19.